Abstract:Objective: To compare the differences in the clinicopathological and molecular biological features between the breast cancer patients with estrogen receptor (ER) + /progesterone receptor (PR) + or ER + /PR - tumors. Methods: The clinicopathological data of 3124 female breast cancer patients with known ER/PR expression status, 2220 being ER + /PR + and 904 being ER + /PR -, and 1484 being ER - /PR -, were analyzed retrospectively. Immunohistochemistry was used to detect the expression of c-erb and cathapsin D in the tumor specimens. Results: The average peak onset age was 50 years in both the ER + /PR + and ER + PR- patients, and the mean age of the ER + /PR + patients was 52.40 years, not significantly different from that of the ER - /PR - patients (52.57 years, P = 0.709). The peak onset age of the ER + patients was 50 years, significantly higher that that of the ER - patients (48 years, P = 0.001), and the mean age of the ER + patients was 52.46 years, significantly higher than that of the ER - patients (51.42 years, P = 0.001). Univariate analysis showed that ER + /PR - tumors tended to be larger. 24.8% of the ER + /PR- patients had 4 or more metastatic lymph nodes, a rate significantly higher than that of the ER + /PR - patients (20.7%, P = 0.004). The tumors of 18% of the ER + /PR - patients were at the grade III, a rate significantly higher than that of the ER + /PR + patients (13.5%, P = 0.008). The strong positivity rate of the ER + /PR + tumors was 23.4%, ignorantly higher than hat of the ER + /PR - tumors (11.2%, P = 0.000). The c-erB-2 positive rate of the ER + /PR + tumors was 19.7%, significantly lower than that of the ER + /PR - tumor group (28.7%, P = 0.000). The cathepsin D positive rate of the ER + /PR - group was 76.9%, significantly higher than that of the ER + /PR- group (71.9%, P = 0.005). Multivariate analysis indicated that positive PR expression was associated with the level of ER (OR = 1.792,95% CI = 1.484-2.164, P = 0.000), cathepsin D(OR = 1.380,95% CI = 1.023 - 1.862,P = 0.035) and c-erbB-2(OR = 0.639,95% CI = 0.463 - 0.883,P = 0.007). Conclusion: ER + /PR + and ER + /PR - tumors may have identical etiology. The mechanism of whether PR is expressed in ER + breast cancer may be caused by different factors, which causing many different aspects. According to these differences, new target of therapy may provide the possibility of improving the response and prognosis for patients with ER + /PR - tumors.

Expression of ER, PR, CerbB-2, PS2, Cathepsin D and its relationship with the clinical pathology in premenopausal patients with breast canceR

Expressions of c-erbB-2, ER, PR and their prognostic correlation in premenopausal and postmenopausal patients with breast cancer.

The expressing signification of estrogen receptorβ in breast cancer

Expression of Estrogen Receptor,progesterone Recptor and C-Erbb-2 in Breast Cancer Tissues

Expressions of Progesterone Receptor a and B in Breast Invasive Ductal Carcinoma and Their Clinical Significance

The Expression of Estrogen Receptor Α, Β in Different Breast Tissues and Its Relation with Breast Cancer

Expression of ER,PR, C-erbB-2 and Ki-67 Genes in Breast Cancer and Their Clinical Significance

Expression of C-Erbb-2,p53,pcna and Nm23 Proteins in Breast Cancer and Their Clinical Significance

Relationship between c-erbB-2 expression and clinicopathological parameters in breast cancer

Expression and Clinical Significance of Bcl-2, ER, PR and C-erbB-2 in Breast Cancer

Clinical Value of the Expression of PTEN Gene,Progesterone Receptor and Estrogen Receptor for Predicting Biological Behaviors and Prognosis of Breast Carcinoma

Molecular Biological Markers Expression in Breast Cancer and Its Relationship with Clinicopathological Features

Clinico-pathological features of ER+/PR+ and ER+/PR-breast tumors:a comparative study of 5211 cases

[Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases].

Expression of C-erbB-2?ER and PR in Primary Breast Carcinoma and Its Clinical Significance

Clinical Pathologic Status and Expression of Tumor Markers in 5,000 Chinese Breast Cancers

A Multivariate Analysis of Clinicopathologic Factors in Lymphatic Metastasis of Breast Cancer

Association of ERβ Expression with the Clinical Pathologic Indexes and Prognostic Biomarkers of Breast Cancer

Expression of ER,PR,Her-2,Ki-67,nm23 and TS and their significance in bilateral primary breast cancer

Expression of E-cadherin, Beta-Catenin, Cathepsin D, Gelatinases and Their Inhibitors in Invasive Ductal Breast Carcinomas

Correlation of Expressions of ER, PR and C-Erbb-2 to Clinicopathologic Factors in Breast Cancer